The chi-square comparison showed that participants with ALT levels >36 U/L had a tendency towards a higher prevalence of MetS (76.7% vs. 57.3%, p = 0.001) compared with the prevalence of those with ALT levels ≤36 U/L. This evidence concerns the gene GPT and metabolic syndrome.